Literature DB >> 19213023

Novel UBE3A mutations causing Angelman syndrome: different parental origin for single nucleotide changes and multiple nucleotide deletions or insertions.

Cristina Camprubí1, Miriam Guitart, Elisabeth Gabau, Maria Dolors Coll, Sergi Villatoro, Silvestre Oltra, Monica Roselló, Irene Ferrer, Sandra Monfort, Carmen Orellana, Francisco Martínez.   

Abstract

Angelman syndrome (AS) is a genetic disorder caused by a deficiency of UBE3A imprinted gene expression from the maternal chromosome 15. In 10% of AS cases the genetic cause is a mutation affecting the maternal copy of the UBE3A gene. In two large Spanish series of clinically stringently selected and nonstringently selected patients, we have identified 11 pathological mutations--eight of them novel mutations--and 14 sequence changes considered polymorphic variants. Remarkably, single nucleotide substitutions are more likely to be inherited, while multiple nucleotide deletions or insertions are less frequently inherited, thus indicating that single nucleotide substitutions are more likely to originate from the paternal germline. Additionally, there seems to be a different distribution of nucleotide changes and multiple nucleotide deletions or insertions along the UBE3A gene sequence. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19213023     DOI: 10.1002/ajmg.a.32659

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  10 in total

1.  Spontaneous seizures and altered gene expression in GABA signaling pathways in a mind bomb mutant zebrafish.

Authors:  Gabriela A Hortopan; Matthew T Dinday; Scott C Baraban
Journal:  J Neurosci       Date:  2010-10-13       Impact factor: 6.167

2.  Molecular and Clinical Aspects of Angelman Syndrome.

Authors:  A Dagli; K Buiting; C A Williams
Journal:  Mol Syndromol       Date:  2011-07-28

Review 3.  Angelman syndrome - insights into a rare neurogenetic disorder.

Authors:  Karin Buiting; Charles Williams; Bernhard Horsthemke
Journal:  Nat Rev Neurol       Date:  2016-09-12       Impact factor: 42.937

4.  Evaluation of visual evoked potentials in patient with angelmans syndrome - case report.

Authors:  Tatjana Knezevic; Ivana Petronic; Dejan Nikolic; Dragana Cirovic; Vera Krstic; Sinisa Ducic; Ljubica Konstantinovic; Calogero Foti
Journal:  Balkan Med J       Date:  2013-06-01       Impact factor: 2.021

5.  Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations.

Authors:  Stijn N V Bossuyt; A Mattijs Punt; Ilona J de Graaf; Janny van den Burg; Mark G Williams; Helen Heussler; Ype Elgersma; Ben Distel
Journal:  Hum Mol Genet       Date:  2021-04-30       Impact factor: 6.150

6.  A novel UBE3A sequence variant identified in eight related individuals with neurodevelopmental delay, results in a phenotype which does not match the clinical criteria of Angelman syndrome.

Authors:  Amber Geerts-Haages; Stijn N V Bossuyt; Inge den Besten; Hennie Bruggenwirth; Ineke van der Burgt; Helger G Yntema; A Mattijs Punt; Alice Brooks; Ype Elgersma; Ben Distel; Marlies Valstar
Journal:  Mol Genet Genomic Med       Date:  2020-09-05       Impact factor: 2.183

7.  Identification of disease-linked hyperactivating mutations in UBE3A through large-scale functional variant analysis.

Authors:  Kellan P Weston; Xiaoyi Gao; Jinghan Zhao; Kwang-Soo Kim; Susan E Maloney; Jill Gotoff; Sumit Parikh; Yen-Chen Leu; Kuen-Phon Wu; Marwan Shinawi; Joshua P Steimel; Joseph S Harrison; Jason J Yi
Journal:  Nat Commun       Date:  2021-11-23       Impact factor: 14.919

8.  An Analysis of Phenotype and Genotype in a Large Cohort of Chinese Children with Angelman Syndrome.

Authors:  Xiaonan Du; Ji Wang; Shuang Li; Yu Ma; Tianqi Wang; Bingbing Wu; Yuanfeng Zhou; Lifei Yu; Yi Wang
Journal:  Genes (Basel)       Date:  2022-08-14       Impact factor: 4.141

9.  An Autism-Linked Mutation Disables Phosphorylation Control of UBE3A.

Authors:  Jason J Yi; Janet Berrios; Jason M Newbern; William D Snider; Benjamin D Philpot; Klaus M Hahn; Mark J Zylka
Journal:  Cell       Date:  2015-08-06       Impact factor: 41.582

10.  Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1.

Authors:  Gemma L Carvill; Sinéad B Heavin; Simone C Yendle; Jacinta M McMahon; Brian J O'Roak; Joseph Cook; Adiba Khan; Michael O Dorschner; Molly Weaver; Sophie Calvert; Stephen Malone; Geoffrey Wallace; Thorsten Stanley; Ann M E Bye; Andrew Bleasel; Katherine B Howell; Sara Kivity; Mark T Mackay; Victoria Rodriguez-Casero; Richard Webster; Amos Korczyn; Zaid Afawi; Nathanel Zelnick; Tally Lerman-Sagie; Dorit Lev; Rikke S Møller; Deepak Gill; Danielle M Andrade; Jeremy L Freeman; Lynette G Sadleir; Jay Shendure; Samuel F Berkovic; Ingrid E Scheffer; Heather C Mefford
Journal:  Nat Genet       Date:  2013-05-26       Impact factor: 38.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.